Trial Profile

Long Term Safety Study of Amifampridine Phosphate in Patients With MuSK Antibody Positive and AChR (Acetylcholine Receptor) Antibody Positive Myasthenia Gravis

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 09 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Amifampridine (Primary)
Indications Myasthenia gravis
Focus Adverse reactions; Registrational
Acronyms MSK-003
Sponsors Catalyst Pharmaceuticals

Most Recent Events

15 Apr 2024 Status changed from active, no longer recruiting to discontinued.
14 Apr 2023 Planned End Date changed from 30 Oct 2022 to 28 Apr 2023.
21 Jul 2022 Planned End Date changed from 30 Jun 2022 to 30 Oct 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com